Waters (WAT) Stock Could Be 32% Overvalued After AI Software Launch

Waters Corporation has delivered strong returns in recent years, and the question now is whether the cash it can generate in the future really supports the price on the screen. With a Discounted Cash Flow (DCF) estimate available, the focus turns to how closely that intrinsic value aligns with where Waters trades today.

• Over the past 3 years, Waters has returned 77.6%. This puts a lot of weight on whether the underlying cash flows can carry that kind of share price performance.
• New AI powered peak integration in its Empower software and large scale collaborations in immune profiling and HPV testing can influence expectations for future cash generation, margins, and the timing of cash inflows.
• What if you looked at Waters through its sales instead? See what Waters's 9.8x P/S says about the price.

The issue now is whether Waters' current share price appropriately reflects the cash flows implied by its Discounted Cash Flow (DCF) intrinsic value estimate.

If you want to test the same cash flow question across other AI focused businesses, compare Waters with a broader group of 34 healthcare AI stocks.

Has Waters Run Too Far on Cash Flow?

The Discounted Cash Flow (DCF) approach here takes Waters' future cash generation and brings it back to today in dollar terms. The model starts from latest twelve month free cash flow of about $364.5 million and then assumes that free cash flow grows to a peak in the next few years before easing back toward more moderate levels.

Analyst sourced projections in the model point to growing free cash flow into the late 2020s, with later years based on declining growth estimates, which keeps the long term profile closer to a mature cash generator than a hyper growth story. On these cash flow assumptions, the DCF output sits substantially below the current share price of $462.72, which suggests the market is assigning a richer price to Waters than the model supports. The AI powered peak integration for Empower software and large immune profiling and HPV testing partnerships may help explain why investors are willing to pay up despite the more measured cash flow curve implied by the DCF model. Find out what Waters could be worth using our Discounted Cash Flow (DCF) estimate.

The Waters Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where the valuation puzzle for Waters leaves off, by spelling out which paths for growth, profitability and earnings would need to play out for the stock to be worth meaningfully more or less than it trades for today on the market. Rather than relying on a single multiple or one DCF output, each narrative lays out the key assumptions behind its estimated value so you can refer back to them as results are reported, and they sit on Simply Wall St's Community page.

Community narratives on Waters are split between those who see more upside in the AI and diagnostics story and those who think most of that is already priced in.

Bull case: 13% undervalued

"Partnerships such as the IMU Biosciences collaboration on AI based immune profiling and the CellCarta agreement to co develop companion diagnostics…"

Discover why this Narrative puts Waters at 13% undervalued.

Bear case: roughly fairly valued

"Waters' acquisition and integration of BD Biosciences and Diagnostic Solutions still carries meaningful execution risk…"

Explore why this Narrative puts Waters at roughly fairly valued.

The price of Waters is only part of the story

Cash flows and AI projects tell you what the business produces, but the people setting priorities and how they are rewarded can shape everything from risk appetite to capital allocation. See who runs Waters and how they are paid.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com